Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 704-712

  Zhang, Bin ^a,b   Yang, Yan ^c   Shi, Xiaoting ^c   Liao, Wanyu ^a   Chen, Min ^a   Cheng, Alfred Sze Lok ^d   Yan, Hongli ^e   Fang, Cheng ^c   Zhang, Shu ^a   Xu, Guifang ^a   Shen, Shanshan ^a   Huang, Shuling ^a   Chen, Guangxia ^c   Lv, Ying ^a   Ling, Tingsheng ^a   Zhang, Xiaoqi ^a   Wang, Lei ^a   Zhuge, Yuzheng ^a   Zou, Xiaoping ^a,b  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b NANJING UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Epithelial to mesenchymal transition; Invasiveness; Pantoprazole

Indexed keywords

BETA CATENIN; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; PANTOPRAZOLE; PROTEIN KINASE B; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MESSENGER RNA; PROTON PUMP INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; APOPTOSIS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; WOUND HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTON PUMP INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; WNT SIGNALING PATHWAY; WOUND HEALING;

EID: 84919494190     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.016     Document Type: Article

References (37)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30.
2. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev 2010, 19:1893-1907.
3. Smith M.G., Hold G.L., Tahara E., El-Omar E.M. Cellular and molecular aspects of gastric cancer. World J. Gastroenterol 2006, 12:2979-2990.
4. Oka S., Tanaka S., Kaneko I., Mouri R., Hirata M., Kawamura T., et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest. Endosc 2006, 64:877-883.
5. Wohrer S.S., Raderer M., Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann. Oncol 2004, 15:1585-1595.
6. Bamias A., Pavlidis N. Systemic chemotherapy in gastric cancer: where do we stand today?. Oncologist 1998, 3:171-177.
7. Liang Y., McDonnell S., Clynes M. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr. Cancer Drug Targets 2002, 2:257-277.
8. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
9. Kim J.J., Yin B., Christudass C.S., Terada N., Rajagopalan K., Fabry B., et al. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J. Cell. Biochem 2013, 114:1286-1293.
10. Milone M.R., Pucci B., Bruzzese F., Carbone C., Piro G., Costantini S., et al. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis 2013, 4:e641.
11. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
12. Huang J., Xiao D., Li G., Ma J., Chen P., Yuan W., et al. EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells. Oncogene 2014, 33:2737-2747.
13. Wu Y., Ginther C., Kim J., Mosher N., Chung S., Slamon D., et al. Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol. Cancer Res 2012, 10:1597-1606.
14. Zhang Q., Bai X., Chen W., Ma T., Hu Q., Liang C., et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013, 34:962-973.
15. Gradl D., Kuhl M., Wedlich D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol. Cell. Biol 1999, 19:5576-5587.
16. Brabletz T., Jung A., Dag S., Hlubek F., Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol 1999, 155:1033-1038.
17. Lu Z., Ghosh S., Wang Z., Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4:499-515.
18. Murata-Kamiya N., Kurashima Y., Teishikata Y., Yamahashi Y., Saito Y., Higashi H., et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 2007, 26:4617-4626.
19. Chen M., Huang S.L., Zhang X.Q., Zhang B., Zhu H., Yang V.W., et al. Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro and in vivo. J. Cell. Biochem 2012, 113:2474-2487.
20. Yu J., Cheng Y.Y., Tao Q., Cheung K.F., Lam C.N., Geng H., et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009, 136:640-651. 651.e1.
21. Maseki S., Ijichi K., Tanaka H., Fujii M., Hasegawa Y., Ogawa T., et al. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br. J. Cancer 2012, 106:1196-1204.
22. Feng H., Cheng A.S., Tsang D.P., Li M.S., Go M.Y., Cheung Y.S., et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J. Clin. Invest 2011, 121:3159-3175.
23. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol 2005, 17:548-558.
24. Kendziorra E., Ahlborn K., Spitzner M., Rave-Frank M., Emons G., Gaedcke J., et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-)radiotherapy. Carcinogenesis 2011, 32:1824-1831.
25. Shen W., Zou X., Chen M., Shen Y., Huang S., Guo H., et al. Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phosphoLRP6 expression in Wnt/beta-catenin signaling. Oncol. Rep 2013, 30:851-855.
26. Ding Q., Xia W., Liu J.-C., Yang J.-Y., Lee D.-F., Xia J., et al. Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin. Mol. Cell 2005, 19:159-170.
27. Chen Z., Zhang L., Xia L., Jin Y., Wu Q., Guo H., et al. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014, 350:43-51.
28. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn P.A., et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther 2007, 6:1683-1691.
29. Yang J., Yu H., Shen M., Wei W., Xia L., Zhao P. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation. Cancer Sci 2014, 105:219-227.
30. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009, 69:5820-5828.
31. Li W., Liu C., Tang Y., Li H., Zhou F., Lv S. Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. Asian Pac. J. Cancer Prev 2011, 12:2575-2580.
32. Han R., Xiong J., Xiao R., Altaf E., Wang J., Liu Y., et al. Activation of beta-catenin signaling is critical for doxorubicin-induced epithelial-mesenchymal transition in BGC-823 gastric cancer cell line. Tumour Biol 2013, 34:277-284.
33. Luciani F., Spada M., De Milito A., Molinari A., Rivoltini L., Montinaro A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst 2004, 96:1702-1713.
34. De Milito A., Iessi E., Logozzi M., Lozupone F., Spada M., Marino M.L., et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007, 67:5408-5417.
35. Yeo M., Kim D.K., Kim Y.B., Oh T.Y., Lee J.E., Cho S.W., et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin. Cancer Res 2004, 10:8687-8696.
36. Shen Y., Wu Y., Chen M., Shen W., Huang S., Zhang L., et al. Effects of pantoprazole as a HIF-1alpha inhibitor on human gastric adenocarcinoma sgc-7901 cells. Neoplasma 2012, 59:142-149.
37. Chen M., Zou X., Luo H., Cao J., Zhang X., Zhang B., et al. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol. Int 2009, 33:1008-1019.